noscript

News and Announcements

CEO Dr James Garner interviewed for CommSec’s Executive Series

  • Published October 29, 2019 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Kazia’s CEO, Dr James Garner, was recently interviewed by Tom Piotrowski for CommSec’s Executive Series.

In the interview, Dr Garner discusses:

  • Kazia’s recent $4mn capital raising, including the reasons behind the timing of the raise and why it was important to have the raise supported by specialist institutional investors.
  • The Company’s recent efficacy data from its Cantrixil trial in ovarian cancer and the significance of treating patients in the later stages of the disease.
  • The upcoming release of first efficacy data from Kazia’s phase II study of GDC-0084 in glioblastoma, expected in November.
  • Kazia’s recent win in the inaugural ANZLF Trans-Tasman Innovation + Growth Awards.

For more information on Kazia’s recent capital raise, read the ASX Announcement here

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Register Interest

 

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now